

CORRECTION

Open Access



Correction to: Association of tobacco product use with chronic obstructive pulmonary disease (COPD) prevalence and incidence in waves 1 through 5 (2013–2019) of the population assessment of tobacco and health (PATH) study

Laura M. Paulin^{1*}, Michael J. Halenar², Kathryn C. Edwards², Kristin Lauten², Cassandra A. Stanton², Kristie Taylor², Dorothy Hatsukami³, Andrew Hyland⁴, Todd MacKenzie¹, Martin C. Mahoney⁴, Ray Niaura⁵, Dennis Trinidad⁶, Carlos Blanco⁷, Wilson M. Compton⁷, Lisa D. Gardner⁸, Heather L. Kimmel⁷, Dana Lauterstein⁸, Daniela Marshall^{7,9} and James D. Sargent¹

Correction to: *Respiratory Research* (2022) 23:273
<https://doi.org/10.1186/s12931-022-02197-1>

In the original publication of this article [1], the co-author “Ray Niaura” has provided the following declaration statement “Between mid-2015 and 2020, Dr. Niaura

frequently communicated with Juul Labs personnel, for which there was no compensation, and received hospitality in the form of meals at some meetings” to be added under “Competing interests” section. The updated completing interests is given below.

Competing interests

Martin C. Mahoney has provided expert testimony on the health effects of smoking in lawsuits filed against the tobacco industry. He has also received research support from Pfizer, Inc., for a clinical trial of smoking cessation, and has previously served on external advisory panels sponsored by Pfizer to promote smoking cessation in clinical settings. Raymond Niaura receives funding from the Food and Drug Administration Center for Tobacco Products via contractual mechanisms with Westat and the National Institutes of Health. Within the past 3 years, he has served as a paid consultant to the Government of Canada via a contract with Industrial Economics Inc. and has received an honorarium for a virtual meeting from Pfizer Inc. Dr. Niaura was an unpaid grant reviewer for the Foundation for a Smoke Free World. Wilson Compton reports long-term stock holdings in General Electric,

The online version of the original article can be found at <https://doi.org/10.1186/s12931-022-02197-1>

*Correspondence:

Laura M. Paulin
Laura.m.paulin@hitchcock.org

¹Geisel School of Medicine at Dartmouth, The C. Everett Koop Institute at Dartmouth, Hanover, NH, USA

²Behavioral Health and Health Policy Practice, Westat, Rockville, MD, USA

³Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, MN, USA

⁴Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

⁵New York University School of Global Public Health, New York, NY 10012, USA

⁶University of California at San Diego, La Jolla, CA 92037, USA

⁷National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA

⁸Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA

⁹Kelly Government Solutions, Rockville, MD, USA



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

3 M Company, and Pfizer Incorporated, unrelated to this article. Between mid-2015 and 2020, Dr. Niaura frequently communicated with Juul Labs personnel, for which there was no compensation, and received hospitality in the form of meals at some meetings.

Published online: 08 March 2025

References

1. Paulin LM, Halenar MJ, Edwards KC, et al. Association of tobacco product use with chronic obstructive pulmonary disease (COPD) prevalence and incidence in waves 1 through 5 (2013–2019) of the population assessment of tobacco and health (PATH) study. *Respir Res.* 2022;23:273.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.